• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Prophylactic nirsevimab protects infants from respiratory syncytial virus infection

byBoaz WongandHarsh Shah
March 7, 2022
in Chronic Disease, Infectious Disease, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Single-dose intramuscular injection of nirsevimab significantly reduced respiratory syncytial virus (RSV) infection in infants.

2. Nirsevimab was shown to reduced associated hospitalizations in infants.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Respiratory syncytial virus (RSV) is a seasonal virus that poses a significant threat to newborns for lower respiratory tract infection leading to hospitalization. To combat this, nirsevimab, which is a monoclonal antibody that prevents RSV viral entry, can be administered prophylactically. Given its favorable safety profile and efficacy data in preterm infants, this phase 3 randomized control trial sought to investigate the efficacy of nirsevimab in late preterm and term infants. Infants born with a gestational age of at least 35 weeks were randomized in a 2:1 ratio to either receive one intramuscular dose of nirsevimab prior to the start of RSV season, or a placebo. The primary outcome for this study was the rate of RSV-associated infection at 150 days follow-up, while secondary endpoints looked at rates of hospitalization in the same time frame. The study found that infants receiving nirsevimab indeed had significant rates of RSV infection and associated hospitalization at 150 days follow-up. Rates of serious adverse events were similar between both groups supporting a favorable safety profile. Taken together, this study supports the use of nirsevimab before RSV season to lower rates of RSV-associated infection and hospitalization. This study was limited by a smaller than desired study size, but more importantly, decreased overall rates of RSV infection, both due to the COVID-19 pandemic.

Click to read the study in NEJM 

Relevant Reading: A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants

In-Depth [randomized controlled trial]: In this phase 3 randomized control trial, 1490 infants born with a gestational age of at least 35 weeks (late pre-term or term) were randomized in a 2:1 ratio, stratified for hemisphere and age, to receive a single intramuscular injection of nirsevimab or placebo. The primary endpoint assessed the percentage of infants with RSV-caused lower respiratory tract infection, as defined by positive polymerase-chain-reaction assay or RSV-associated clinical signs, at 150 days post-injection. The secondary endpoints analyzed the percentage of infants hospitalized due to RSV infection within the same follow-up period and safety profile. Differences in proportions between groups were statistically analyzed by the Poisson regression model with robust variance. The results of the study found that nirsevimab was able to significantly reduce the proportion of infants who contracted RSV-associated lower respiratory tract infections with 74.5% efficacy (95% confidence interval [CI], 49.6 – 87.1; P<0.001). Similarly, infants treated with nirsevimab have a lower proportion of RSV-associated hospitalization at 0.6% compared to 1.6% in the placebo group, albeit not with significant efficacy (P=0.07). Similar rates of severe adverse events were experienced between both groups (nirsevimab, 6.8%; placebo, 7.3%) with 3 deaths occurring in the nirsevimab group. Pharmacokinetics and antibody titer data were comparable to previous studies. Overall, this study supports the use of single intramuscular administration of nirsevimab for the prevention of RSV infection and hospitalization in late preterm and term infants.

RELATED REPORTS

Aggressive hydration does not improve clinical outcomes in acute pancreatitis

Early peanut introduction was not associated with lower prevalence of peanut allergy

Wellness check: Nutrition

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: hospitalizationinfantnirsevimabpediatric hospitalizationsprophylacticrespiratory syncytial virus (RSV)
Previous Post

Higher step counts may result in lower risk of adverse outcomes

Next Post

Impact of changes in guidelines for management billing codes guidelines

RelatedReports

VEGFR-targeted ultrasound may improve detection of pancreatic cancer
Emergency

Aggressive hydration does not improve clinical outcomes in acute pancreatitis

November 21, 2022
Peanut allergy effectively treated with oral immunotherapy: the PALISADE trial
Gastroenterology

Early peanut introduction was not associated with lower prevalence of peanut allergy

August 9, 2022
Diet may play role in fertility
Wellness

Wellness check: Nutrition

August 17, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

The RECOVERY trial: Dexamethasone decreased mortality in hospitalized COVID-19 patients [Classics Series]

July 16, 2022
Next Post

Impact of changes in guidelines for management billing codes guidelines

Nonmedical expenses of pediatric hospitalizations have disproportionate effects

Pertuzumab has clinical benefits in metastatic breast cancer but is not cost-effective

Novel coronavirus identified from patients with pneumonia in Wuhan, China

AD26.COV2.S vaccine provides protection against Covid-19

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options